Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Coordination and Support Action · Running

i3S-HEALTH Teaming to Drive the Future of Genomic Medicine

Coordinator
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do Porto, Portugal
Runs
1 January 2027 to 31 December 2032
Status
Running
EU funding
€15.0m
Total cost
€15.0m
Partners
4 organisations in 2 countries
Type
Coordination and Support Action
Grant agreement
101250351

What the project is doing

In the project's own words, from its summary on CORDIS.

Genomic medicine is transforming healthcare through precise, personalized solutions that enhance patient outcomes. However, Portugal faces significant challenges, including limited genomic sequencing, fragmented clinical applications, and a shortage of specialized talent. i3S-HEALTH aims to address these issues by modernizing the Institute for Research and Innovation in Health (i3S) into a global Centre of Excellence in Genomic Medicine under the guidance of the European Molecular Biology Laboratory (EMBL) as an advanced partner. i3S-HEALTH will establish a state-of-the-art Genomic Medicine Hub that uniquely integrates next-generation sequencing, computational biology, AI-driven bioinformatics, and high-throughput functional genomics for new variants discovery to improve patient care.

This initiative will be Portugal's first multidisciplinary platform connecting advanced genomic research with clinical diagnostics. Key expected outcomes will include expanded diagnostic capacity and accuracy, trained specialists, developing novel predictive algorithms for complex genetic conditions, and identifying actionable multi-omics biomarkers. i3S-HEALTH will enrich the genomic medicine landscape in Portugal and Europe by strategically engaging the scientific community to accelerate genomic discoveries and foster high-impact collaborations with healthcare providers, improving clinical decision-making through better diagnostics and personalized patient care.

It will also collaborate with industry to co-develop innovative diagnostics and therapeutics in public-private partnerships. Increased revenues from advanced diagnostic services, strategic industry partnerships, new projects, IP development, and the launch of genomics spin-offs will ensure sustainability beyond the project. i3S-HEALTH will directly strengthen national R&I performance in genomic medicine, positioning i3S as a leading European center for innovation and excellence in genomic healthcare research.

Topics

Who is involved

OrganisationCityCountryRole
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do PortoPortoPortugalCoordinator
European Molecular Biology LaboratoryHeidelbergGermanyParticipant
Instituto De Biologia Molecular E Celular-IbmcPortoPortugalThird party
Ipatimup - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto PcupPortoPortugalThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI